Home / People / Fionnuala Rice
Portrait of Fionnuala Rice

Fionnuala Rice

Senior Associate

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Fionnuala is a Senior Associate in the Intellectual Property department.

more less

Education

  • 2016 – Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford
  • 2010 – Legal Practice Course, BPP Law School, London
  • 2009 – Graduate Diploma in Law, Oxford Brookes University
  • 2008 – BA (Hons) Physiological Sciences, University of Oxford
more less
Get in contact with

Feed

29 October 2020
EU Gen­er­al Court cla­ri­fies in­ter­pret­a­tion of “sat­is­fact­ory meth­od” in the...
In the re­cent case of Me­dac Gesell­schaft für klin­is­che Spezi­al­prä­par­ate mbH v European Com­mis­sion, the EU Gen­er­al Court has an­nulled a de­cision of the European Com­mis­sion in which it held that the ap­plic­ant’s...
18 June 2020
MHRA re­leases up­dated guid­ance on med­ic­al device soft­ware and apps
On 4 June 2020, the Medi­cines and Health­care products Reg­u­lat­ory Agency (“MHRA”) pub­lished its up­dated guid­ance on med­ic­al device stand-alone soft­ware, which is in­ten­ded to cla­ri­fy the types of soft­ware...
06 March 2020
MDR - Agree­ments with third party con­tract man­u­fac­tur­ers
The EU Med­ic­al Device Reg­u­la­tion, which comes in­to force on 26 May 2020, will lead not only to big changes in how med­ic­al devices are reg­u­lated, but also to more thought be­ing giv­en to agree­ments between...
07 February 2020
MHRA up­dates guid­ance on with­draw­al of no­ti­fied body ser­vices (UK)
The Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) has re­cently is­sued guid­ance for situ­ations where a no­ti­fied body with­draws all, or part, of its ser­vices in re­la­tion to med­ic­al devices...
13 December 2018
Di­git­al Health - The new reg­u­la­tion of med­ic­al soft­ware and apps
The new Med­ic­al Devices Reg­u­la­tion 2017/745 (“MDR”), which comes in­to force in May 2020, rep­res­ents a huge over­haul of the reg­u­lat­ory frame­work gov­ern­ing med­ic­al devices in the EU.  The com­pli­ance...
15 August 2018
New MHRA guid­ance on Brexit im­ple­ment­a­tion peri­od and the lifes­ci­ences...
On 6 Au­gust 2018, the MHRA re­leased new guid­ance on what the Brexit im­ple­ment­a­tion peri­od means for the lifes­ci­ences sec­tor, as well as an up­date on the ap­plic­a­tion of the new EU Clin­ic­al Tri­als Reg­u­la­tion...
3 August 2018
CMS ad­vises lead­ing In­ter­net-of-Things pro­vider Arkessa in deal with ECI...
In­ter­na­tion­al law firm CMS has ad­vised on the man­age­ment buy­out of Arkessa, the lead­ing In­ter­net-of-Things (“IoT”) man­aged ser­vices pro­vider, to private equity firm ECI Part­ners. Arkessa en­ables en­ter­prises...
24 April 2018
Shire v EMA: Cla­ri­fic­a­tion on orphan des­ig­na­tion for products with the...
On 22 March 2018 the EU Gen­er­al Court handed down its judg­ment in Case T-80/16 Shire Phar­ma­ceut­ic­als Ire­land Ltd v European Medi­cines Agency (EMA). The case centred around wheth­er a new medi­cin­al product...